Gilead Sciences IncGILD:NSQ

1.72 / 1.73 %
7.22 %
Close in USDToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Oct 06 2015 21:00 BST.

Consensus recommendation

As of Oct 05, 2015, the consensus forecast amongst 21 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
No opinion0

Research Reports

S&P Capital IQ – STARS Reports
Ford Investor Services, Inc.

Share price forecast

The 16 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 128.00, with a high estimate of 141.00 and a low estimate of 98.00. The median estimate represents a 28.95% increase from the last price of 99.26. View Full Financials

High+44.6 %141.00
Med+31.2 %128.00
Low+0.5 %98.00


Historical dividend information is not available for Gilead Sciences Inc. View Full Financials

Div growth (TTM)--
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Jul 28, 2015, Gilead Sciences, Inc. reported 2nd quarter 2015 earnings of 3.15 per share. This result exceeded the 2.69 consensus of the 17 analysts covering the company and exceeded last year's 2nd quarter results by 33.47%.
The next earnings announcement is expected on Oct 26, 2015. View Full Interim Financials

Average growth rate+8.38 %

Gilead Sciences, Inc. reported annual 2014 earnings of 8.09 per share on Feb 03, 2015. View Full Annual Financials

Average growth rate+76.71 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement


Gilead Sciences Inc. had 2nd quarter 2015 revenues of 8.24bn. This bettered the 7.56bn consensus of the 16 analysts covering the company. This was 26.15% above the prior year's 2nd quarter results. View Full Interim Financials

Average growth rate+6.47 %

Gilead Sciences Inc. had revenues for the full year 2014 of 24.89bn. This was 122.20% above the prior year's results. View Full Annual Financials

Average growth rate+39.71 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.